ExodusPoint Capital Management LP Purchases 993,496 Shares of Pfizer Inc. $PFE

ExodusPoint Capital Management LP raised its position in shares of Pfizer Inc. (NYSE:PFE) by 203.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,482,551 shares of the biopharmaceutical company’s stock after purchasing an additional 993,496 shares during the quarter. ExodusPoint Capital Management LP’s holdings in Pfizer were worth $36,916,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Triad Wealth Partners LLC increased its stake in Pfizer by 1.9% during the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 386 shares in the last quarter. ETF Store Inc. increased its stake in Pfizer by 3.8% during the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after purchasing an additional 396 shares in the last quarter. Mattern Wealth Management LLC increased its stake in Pfizer by 4.6% during the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after purchasing an additional 400 shares in the last quarter. Pines Wealth Management LLC increased its stake in Pfizer by 4.4% during the 4th quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 400 shares in the last quarter. Finally, Pathway Financial Advisers LLC boosted its holdings in shares of Pfizer by 0.9% during the 4th quarter. Pathway Financial Advisers LLC now owns 46,380 shares of the biopharmaceutical company’s stock valued at $1,155,000 after acquiring an additional 403 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

Shares of NYSE PFE opened at $26.04 on Wednesday. The firm’s 50-day moving average price is $26.34 and its 200-day moving average price is $26.34. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The company has a market cap of $148.41 billion, a PE ratio of 19.88 and a beta of 0.34. Pfizer Inc. has a 52-week low of $23.11 and a 52-week high of $28.75.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm’s revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 8th were issued a $0.43 dividend. The ex-dividend date of this dividend was Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent analyst reports. Citigroup raised their price target on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. CICC Research initiated coverage on shares of Pfizer in a report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price target on the stock. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a report on Monday, March 2nd. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Finally, Guggenheim raised their price target on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus target price of $28.82.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s obesity pipeline gained traction after detailed Phase 2b data for berobenatide showed proof of concept, favorable tolerability, and low reported adverse events. Pfizer has already moved the program into Phase 3, which could support longer-term growth expectations. Pfizer Obesity Pipeline Gains Traction As Berobenatide Data Support Valuation
• Positive Sentiment: CEO comments that Pfizer could return to high-single-digit growth suggest the business may be stabilizing faster than some investors expected, reinforcing the idea that the company’s recent weakness may be overdone. Here’s When Pfizer’s CEO Says the Company Might Get Back to Generating High-Single-Digit Growth
• Neutral Sentiment: Pfizer is drawing heavy investor interest and analyst coverage, with recent research pieces focusing on its discounted valuation, pipeline prospects, and post-COVID growth outlook. That keeps sentiment active, but the articles do not point to a single new catalyst. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Pfizer also remained in the news through broader healthcare coverage and research roundups, but these items appear informational rather than stock-moving. Top Research Reports for Pfizer, Altria & Newmont Corp.
• Negative Sentiment: Some coverage continues to frame Pfizer as a value stock facing fading COVID revenue and looming patent-cliff pressure, which reminds investors of the company’s near-term growth challenges even as pipeline efforts progress. Is Pfizer’s Discounted Valuation a Buying Opportunity or a Value Trap?

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.